Publications by authors named "Marc A Pohl"

Claim this Profile
I
In Reply: Blood pressure targets.
George Thomas, Joseph V Nally, Marc A Pohl

Cleve Clin J Med· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interpreting SPRINT: How low should you go?
George Thomas, Joseph V Nally, Marc A Pohl

Cleve Clin J Med· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pyridorin in type 2 diabetic nephropathy.
Edmund J Lewis, Tom Greene, Samuel Spitalewiz, Samuel Blumenthal, Tomas Berl, Marc A Pohl

J Am Soc Nephrol· January 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sulodexide for kidney protection in type 2 diabetes patients with microalbuminuria: a randomized controlled trial.
Edmund J Lewis, Julia B Lewis, Tom Greene, Lawrence G Hunsicker, Tomas Berl, Marc A Pohl

Am J Kidney Dis· November 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: clinical implications and limitations.
Marc A Pohl, Samuel Blumenthal, Daniel J Cordonnier, Fernando De Alvaro, Giacomo Deferrari

J Am Soc Nephrol· October 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Relation of homocysteine and C-reactive protein to urinary albumin loss.
Niranjan Seshadri, Adrian W Messerli, Naveen Acharya, Gregory L Pearce, Donald W Jacobsen, Marc A Pohl

Am J Cardiol· April 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis